Drug development
and diagnostics
Choose the relevant keywords from the list to search for research groups on those specific areas. As the search is cumulative, choose only a few keywords for a general search and more keywords for more refined search. To see all research groups, click the selection underneath the list.
Screening Unit
Main categories: Drug discovery
The screening unit offers academic researchers and industrial customers a broad range of services for identifying and optimising bioactive molecules for the drug discovery process. These include molecular modelling and in silico screening, development of screening assays and compound library screens, in vitro and in situ hit validation, hit optimisation and SAR analyses. A suite of cell and tissue-based disease models for oncology and neurological diseases are available for further validation of optimised hits or for independent phenotypic screens. High-throughput kinetic assays of changes in morphology or intracellular signalling over time may be integrated into chemical, genetic or optogenetic perturbation screens. A library of reporters in gene-delivery vectors are available for this purpose. The unit also has experience performing screens and toxicological evaluations in small animal models.
Contact details
High-throughput screens, screen-compatible assays, high-throughput microscopy, libraries, optogenetics, cell-based neurological disease models:
michael.courtney[at]utu.fi
3D oncology models, phenotypic screens, high-content screens:
malin.akerfelt[at]utu.fi
Medicinal chemistry, virtual screening and molecular modelling:
olli.pentikainen[at]utu.fi
Drug development and diagnostics is a common research profiling area of the University of Turku and Åbo Akademi University funded by the Academy of Finland. This website is a part of this joint initiative bringing together all information that is related to drug discovery and development or diagnostics from both universities.
